Alzprotect is focused on developing innovative therapeutic solutions for neurodegenerative diseases, particularly targeting tauopathies such as Progressive Supranuclear Palsy (PSP) and Alzheimer’s disease. The company is advancing a drug candidate known as AZP2006, which is an orally available small molecule that operates through a novel mechanism of action. This mechanism distinguishes AZP2006 from other treatments developed over the past 25 years by simultaneously addressing multiple neurodegenerative factors, including amyloid beta peptide, Tau protein, neuroinflammation, and oxidative stress. Preclinical studies have demonstrated that AZP2006 can stimulate the release of the neurotrophic factor progranulin, promoting neuronal growth and reducing the aggregation of Tau proteins, thereby protecting neurons and preventing memory loss.

The clinical development of AZP2006 has garnered positive feedback from regulatory authorities such as the FDA and EMA, particularly regarding its Phase 2b/3 development strategy for PSP. The drug has shown excellent safety and tolerability in Phase 1 trials involving healthy volunteers, and promising efficacy in a Phase 2a trial with PSP patients. Alzprotect is poised to initiate a randomized Phase 2b/3 proof of concept trial for PSP and plans to expand its research to include other neurodegenerative diseases like Parkinson's disease and amyotrophic lateral sclerosis. This strategic approach aims to address the urgent needs of patients suffering from these debilitating conditions, leveraging the unique therapeutic potential of AZP2006.

France

Alzprotect is a biopharmaceutical company that develops drug candidates, from their discovery to clinical trials, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and tauopathies such as Progressive Supranuclear Palsy (PSP).

Alzprotect

Company Details